PEPG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PepGen Inc (PEPG) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows insider buying activity, a bullish technical setup, and positive analyst sentiment with a raised price target. Despite financial challenges, the company's clinical-stage pipeline and potential catalysts make it a suitable long-term investment.
The stock's technical indicators are bullish. The MACD is positive and contracting, RSI is neutral at 51.667, and moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). Key support is at 5.945, with resistance at 6.984 and 7.306. The stock has a 70% chance to rise 2.57% in the next day and 6.15% in the next month.
Insider buying has increased by 294713.82% over the last month, signaling confidence in the company.
Analysts have a positive outlook, with Oppenheimer initiating coverage with an Outperform rating and a $15 price target.
Upcoming data from the FREEDOM2 trial in March could serve as a catalyst.
Concerns about kidney safety risks in the Duchenne muscular dystrophy program, which could potentially impact the DM1 program.
Weak financial performance in Q3 2025, with net income dropping by 15.70% YoY and EPS declining by 21.21%.
In Q3 2025, PepGen reported no revenue growth (0% YoY) and a net income loss of -$18.03M, down 15.70% YoY. EPS dropped to -0.52, a 21.21% decline YoY. The company remains in a clinical-stage development phase with no revenue generation.
Analysts are optimistic about PepGen. Oppenheimer initiated coverage with an Outperform rating and a $15 price target, citing potential best-in-class efficacy for DM1. Guggenheim raised its price target to $7 from $6, highlighting positive expectations for the FREEDOM2 trial data in March.
